Skip to Main Content

One of our vendors, Insightin Health, experienced a cybersecurity issue in September 2025. To learn more, view their notice.

When it comes to RSV, You Call the Shots.

Date: 12/15/23

You have the best interest of your patients at heart. More than that, you have their trust. Your patients trust you more than any other source when it comes to vaccines. And your recommendation is the most effective way to ensure they get the ones they need.

You Can Help Protect Your Patients and Your Community.

Respiratory syncytial virus (RSV) is the leading cause of childhood respiratory illness in the United States, resulting in thousands of hospitalizations and hundreds of deaths per year. Infants six months and younger are at highest risk. Prevention is essential to combat the severity of RSV. The Food and Drug Administration (FDA) has approved, and the Centers for Disease Control and Prevention (CDC) recommends, the maternal RSV vaccine and the infant RSV monoclonal antibody, providing two opportunities to protect against the negative effects of RSV.

Maternal RSV Vaccination (Abrysvo)

Pfizer’s bivalent RSVpreF vaccine, Abrysvo is the only RSV vaccine approved for use during pregnancy.

  • A single injection given to pregnant individuals at 32 weeks through 36 weeks gestational age has shown reduction in severe RSV infection ininfants by 81% within 90 days of life and 69% within 180 days of life.
  • Should be given seasonally, September through January.
  • May administer with other vaccines recommended during pregnancy.
  • Provides protection for the infant if maternal vaccination occurred at least 14 days prior to birth.

Infant RSV Monoclonal Antibody (Nirsevimab)

For the 2023-2024 RSV season, there are known supply shortages of Nirsevimab. In areas with shortages, guidance is to encourage maternal RSV vaccination as an alternative.

  • A single intramuscular injection for infants younger than 8 months of age, born during or entering into their first RSV season to prevent severe RSV.
  • Available for infants if maternal RSV not given or if vaccine was given but delivery occurred prior to 34 weeks gestation.
  • Has shown an 80% reduction in RSV-related health care visits and hospitalizations.

Want to Learn More? Visit the Centers for Disease Control and Prevention’s Recommendations for Use of Nirsevimab for the Prevention of RSV Among Infants and Young Children. You can also visit The American College of Obstetricians and Gynecologists (ACOG) clinical guidance on Maternal Respiratory Syncytial Virus Vaccination.

Have questions? Contact your provider relations team at 1-866-595-8133 (TTY: 711), Monday through Friday, 7 a.m. to 7 p.m., or visit Louisiana Healthcare Connections' provider portal for additional information and answers to coding and billing requirements.